Search
Letermovir
go.drugbank.com/drugs/DB12070ApprovedInvestigationalLetermovir recieved approval from the FDA on November 8th, 2017 for use in prophylaxis of cytomegalovirus (CMV) infection in allogeneic hematopoietic stem cell transplant patients.
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseStem bromelain
go.drugbank.com/drugs/DB12249ApprovedThe primary therapeutic use for which stem bromelain is currently and formally indicated is as a burn wound eschar debridement agent that has been approved by the EMA since 2012 and marketed under the … This action allows bromelain to demonstrate a wide range of therapeutic benefits ranging from cardiovascular to anticancer therapy - but the specific mechanisms of action by which it can elicit these effects
Etoperidone
go.drugbank.com/drugs/DB09194ApprovedWithdrawn[T45] Etoperidone was developed by Angelini Francesco ACRAF.[A4909]
Pixantrone
go.drugbank.com/drugs/DB06193ApprovedWithdrawnPatients refractory to treatment, or those who relapse, are discouraged from further anthracycline use due to cumulative cardiotoxicity. … It is similar in structure to anthracyclines such as mitoxantrone, but exerts fewer toxic effects on cardiac tissue. [2] The lower cardio-toxic effects of pixantrone may be explained, in part, by its redox
Deflazacort
go.drugbank.com/drugs/DB11921ApprovedIt is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA. … [A179446,A179449,L6697] This disease usually manifests by muscle weakness in early childhood followed by loss of the ability to walk (ambulation) as early as age 7.
Categories: Corticosteroids for Systemic Use, Corticosteroids for Systemic Use, Plaingamma-Hydroxybutyric acid
go.drugbank.com/drugs/DB01440ApprovedIllicitInvestigationalIt is currently regulated in the US and sold by Jazz Pharmaceuticals under the name Xyrem. However, it is important to note that GHB is a designated Orphan drug (in 1985). … Today Xyrem is a Schedule III drug; however GHB remains a Schedule I drug and the illicit use of Xyrem falls under penalties of Schedule I.
Ketoconazole
go.drugbank.com/drugs/DB01026ApprovedInvestigational[A181802,T116] Ketoconazole was first approved in an oral formulation for systemic use by the FDA in 1981. … [FDA Label] It functions by preventing the synthesis of ergosterol, the fungal equivalent of cholesterol, thereby increasing membrane fluidity and preventing growth of the fungus.
Categories: Antifungals for Topical Use, Antimycotics for Systemic UseDihydrostreptomycin
go.drugbank.com/drugs/DB11512ApprovedVet approvedWithdrawnIn humans, the use of dihydrostreptomycin has been associated with ototoxicity. The FDA withdrew its approval for the use of all drug products containing dihydrostreptomycin sulfate.[L43942]
Thiohexam
go.drugbank.com/drugs/DB14200ApprovedThiohexam is a rubber cure accelerator. It is also a known allergen and dermatological sensitizer. Sensitivity to Thiohexam may be identified with a clinical patch test.
Mixtures: Test Thin-Layer Rapid Use Patch TestAmivantamab
go.drugbank.com/drugs/DB16695ApprovedInvestigationalFDA approved the subcutaneous formulation, RYBREVANT FASPRO™, across all existing and expanded indications of amivantamab, including its use as a first-line, chemotherapy-free combination regimen with … [A235133] Amivantamab was granted FDA approval on 21 May 2021,[L34193] followed by the approval by the EMA on 9 December 2021 [L41474] and Health Canada on 30 March 2022.